BMS’ cash cow Revlimid faces first generic rivals in US
pharmaphorum
MARCH 8, 2022
Bristol-Myers Squibb’s blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 and $10 billion in 2022, with three quarters of the total coming from the US.
52 
Let's personalize your content